the aid library

LIST OPTIONS

Filter

704

Sort by:

Direction:

Download (1155)

View PDF (3014)

Emergence of Zaire Ebola Virus Disease in Guinea — Preliminary Report

S. Baize; D. Pannetier; L. Oesterreich, et al. (2014)

The New England Journal of Medicine Genetic analysis of the virus indicates that it is closely related (97% identical) to variants of Ebola virus (species Zaire ebolavirus) identified earlier in the Democratic Republic of the Congo and Gabon PLEASE download the article from the website!!

Download (52)

View PDF (728)

Übersicht und Empfehlungen zu besorgniserregenden SARS-CoV-2-Virusvarianten (VOC)

Robert-Koch-Institut RKI (2021) C1

Vertreter besorgniserregender Virusvarianten (variants of concern, kurz VOC) wurden weltweit aber auch in Europa, identifiziert. Molekularbiologische Details zu den Varianten sind unter SARS-CoV-2: Virologische Basisdaten und Virusvarianten abrufbar.

Download (59)

View PDF (563)

SARS-CoV-2: Virologische Basisdaten sowie Virusvarianten

Robert-Koch-Institut RKI (2021) C1

Download (58)

View PDF (754)

The effects of virus variants on COVID-19 vaccines

World Health Organization WHO (2021) CC

1 March 2021 This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained series.

Download (52)

View PDF (870)

Coronavirus Variants and Mutations

Corum, J.; and C. Zimmer The New York Times (2021) CC

The NY Times variant tracker is perhaps the most accessible and relevant publication for non-molecular biologists and the general public Each coronavirus contains nearly 30,000 letters of RNA. This genetic information allows the virus to infect cells and hijack them to make new viruses.

Download (88)

View PDF (119)

COVID-19 new variants: Knowledge gaps and research

World Health Organization WHO (2021) C_WHO

n light of the potential risk posed by SARS-CoV-2 variants, in January 2021 WHO organized an ad hoc consultation to discuss the development of an R&D agenda in response to existing and emerging SARS-CoV-2 variants. The key objectives were to identify the critical research questions related to var... more

Download (87)

View PDF (117)

Orientations sur la sécurité biologique en laboratoire en rapport avec la maladie à coronavirus 2019 (‎‎COVID-19)
recommended

Organisation Mondiale de la Santé OMS (2021) C_WHO

‎‎Orientations provisoires, 28 janvier 2021 Dans cette version mise à jour des orientations sur la sécurité biologique en laboratoire en rapport avec le SARS-CoV-2, le virus responsable de la maladie à coronavirus 2019 (COVID-19), les points suivants ont été ajoutés : aspects de... more

Download (45)

View PDF (487)

WHO Sciene in 5 Episode #39 - Update on virus variants

World Health Organization WHO (2021) C_WHO

What are the variants circulating at this time? How are variants classified as variants of interest or concern? What does this mean for the public? Dr Maria Van Kerkhove explains in Science in 5 this week.

Download (97)

View PDF (154)

Policy considerations for implementing a risk-based approach to international travel in the context of COVID-19, 2 July 2021

World Health Organization WHO (2021) C_WHO

Countries across the world are facing diverse epidemiological situations with varying response capacities and access to life saving tools. The World Health Organization (WHO) recommends that national authorities continue to apply a risk-based approach when implementing measures related to COVID-19... more

Download (56)

View PDF (932)

Variants du virus et leurs effets sur les vaccins contre la COVID-19

Organisation Mondiale de la Santé OMS (2021) C_WHO

Cet article fait partie d’une série de notes explicatives sur la mise au point et la distribution de vaccins.

Download (49)

View PDF (698)

Mettre fin à la propagation du virus

Organisation Mondiale de la Santé OMS (2021) C_WHO

Lorsqu’un virus circule largement dans une population et entraîne de nombreuses infections, la probabilité de mutation augmente. Plus un virus a de possibilités de se propager, plus il se réplique – et plus il est susceptible de muter. L’arrêt de la propagation du virus à la source res... more

Download (47)

View PDF (803)

WHO’s Science in 5 Episode #63 - Omicron variant
recommended

World Health Organization WHO (2022) C_WHO

What do we know about Omicron variant so far? WHO's Dr Maria Van Kerkhove updates on the transmissibility, severity, symptoms and ways to protect yourself in Science in 5.

Download (136)

View PDF (166)

Covid-19 Test to Treat Guidelines
recommended

African Union; Africa CDC Centres for Disease Control and Prevention (2022) C1

n response to the outbreak, the Africa Centres for Disease Control and Prevention (Africa CDC) has been supporting African Union Member States in responding to the COVID-19 pandemic through a variety of interventions such as non-pharmaceutical interventions, quarantine, testing, isolation, contact t... more

Download (119)

View PDF (167)

Update 80: What we know about new COVID-19 Variants of Concern - the latest on the global situation & Omicron BA.4/5

World Health Organization WHO (2022) C_WHO

While COVID-19 virus continues to circulate and evolve, new variants are constantly emerging. Most of the current COVID-19 cases are driven by the circulation of the BA.5 subvariant of Omicron. The COVID-19 vaccines are being updated with Omicron variants to provide broader immunity against circulat... more

Download (105)

View PDF (165)

Dengue epidemiology

Jing, Q.; Wang, M. Global Health Journal (2019) CC

Dengue is the fastest spreading, mosquito-borne viral infectious disease worldwide, with remarkable morbidity and mortality. In the past decades, profound contributions have been made towards understanding its epidemiology, including disease burden and distributions, risk factors, and control and pr... more

Download (145)

View PDF (156)

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 13 January 2023

World Health Organisation (WHO) (2023) C_WHO

The WHO continuously reviews available data on SARS-CoV-2 variants of concern. For this version, the global epidemiological situation of the COVID-19 pandemic as of 21 January 2022 – at a time when the Omicron VOC had been identified in 171 countries across all six WHO Regions and was rapidly re... more

Download (90)

View PDF (128)

Compendium of Animal Rabies Prevention and Control, 2016

Brown C.M., Slavinski S., Ettestad P. et al National Association of State Public Health Veterinarians Compendium of Animal Rabies Prevention and Control Committee (2016) C2

Rabies is a fatal viral zoonosis and serious public health problem.1 All mammals are believed to be susceptible to the disease, and for the purposes of this document, use of the term animal refers to mammals. The disease is an acute, progressive encephalitis caused by viruses in the genus Lyssavirus... more

Download (245)

View PDF (329)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (64)

View PDF (42)

Epidemiological Alert Mpox (MPXV clade I) - 8 August 2024

World Health Organisation (WHO) (2024) C_WHO

Given the circulation of the variant of clade I of mpox virus (MPXV) in the African Region, which is associated in the African Region with sustained transmission and the occurrence of cases in a wider range of age groups, including children, the Pan American Health Organization/World Health Organiza... more

Download (3)

View PDF (2)

Mpox Testing Strategy - November 2024

Africa Center for Disease Control and Prevention (2024) CC

Mpox is an emerging zoonotic disease caused by the mpox virus, a member of the Orthopoxvirus genus closely related to the variola virus that causes smallpox. Mpox was first discovered in 1958 when outbreaks of a pox-like disease occurred in monkeys kept for research. The first human case was recorde...d in 1970 in the Democratic Republic of the Congo (DRC) during a period of intensified effort to eliminate smallpox and since then the infection has been reported in a number of African countries. Mpox can spread in humans through close contact, usually skin-to-skin contact, including sexual contact, with an infected person or animal, as well as with materials contaminated with the virus such as clothing, beddings and towels, and respiratory droplets in prolonged face to face contact. People remain infectious from the onset of symptoms until all the lesions have scabbed and healed. The virus may spread from infected animals through handling infected meat or through bites or scratches. Diagnosis is confirmed by polymerase chain reaction (PCR) testing of material from a lesion for the virus’s DNA. Two separate clades of the mpox virus are currently circulating in Africa: Clade I, which includes subclades Ia and Ib, and Clade II, comprising subclades IIa and IIb. Clade Ia and Clade Ib have been associated with ongoing human-to-human transmission and are presently responsible for outbreaks in the Democratic Republic of the Congo (DRC), while Clade Ib is also contributing to outbreaks in Burundi and other countries. In 2022‒2023 mpox caused a global outbreak in over 110 countries, most of which had no previous history of the disease, primarily driven by human-to-human transmission of clade II through sexual contact. In just over a year, over 90,000 cases and 150 deaths were reported to the WHO. For the second time since 2022, mpox has been declared a global health emergency as the virus spreads rapidly across the African continent. On 13 Aug 2024, Africa CDC declared the ongoing mpox outbreak a Public Health Emergency of Continental Security (PHECS), marking the first such declaration by the agency since its inception in 2017.7 This declaration empowered the Africa CDC to lead and coordinate responses to the mpox outbreak across affected African countries. On August 14, 2024, the WHO declared the resurgence of mpox a Public Health Emergency of International Concern (PHEIC) emphasizing the need for coordinated international response. As of August 2024, Mpox has expanded beyond its traditional endemic regions, with new cases reported in countries including Sweden, Thailand, the Philippines, and Pakistan. Sweden has confirmed its first case of Clade 1 variant, which has been rapidly spreading in Africa, particularly in DRC. The emergence of this new variant raises concerns about its potential for higher lethality and transmission rates outside Africa. more

Orientations sur la sécurité biologique en laboratoire en rapport avec la maladie à coronavirus 2019 (‎‎COVID-19) recommended

WHO’s Science in 5 Episode #63 - Omicron variant recommended

Covid-19 Test to Treat Guidelines recommended

Orientations sur la sécurité biologique en laboratoire en rapport avec la maladie à coronavirus 2019 (‎‎COVID-19)
recommended

WHO’s Science in 5 Episode #63 - Omicron variant
recommended

Covid-19 Test to Treat Guidelines
recommended